Abbott and Flatiron Health have announced the integration of Abbott’s Precision Oncology test portfolio into OncoEMR, Flatiron’s cloud-based electronic medical record platform. The integration enables oncology providers to digitally order and receive results for Abbott tests – including Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard – directly within their existing clinical workflow.
The move expands access across Flatiron’s network of more than 1,600 community cancer care centers serving 4,700 providers. Quincy Weatherspoon, VP and GM of Point of Care Solutions at Flatiron, said the integration is “reducing friction in the workflow,” while Brian Baranick, VP of Precision Oncology at Abbott, noted it “removes a key barrier to accessing our portfolio at the point of care.”
Flatiron Health, a member of the Roche Group, operates one of the largest oncology-specific EHR platforms in the United States, making this partnership a significant channel for Abbott’s recently expanded cancer diagnostics business.